Asset profile
FB825
Monoclonal antibody
Evidence outlook · results not reported
NCT05059509 · Atopic Dermatitis
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT05059509: This was an open-label study with no control group and no blinding, so any change seen cannot be reliably attributed to the drug rather than natural variation; results have not been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 35 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| FB825: this drug | Phase 2 | Monoclonal antibody | CεmX domain of membrane-bound IgE (mIgE) | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 | ||
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | ||
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| ADSTEM | Phase 3 | Cell therapy | autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy | ||
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | ||
| Asivatrep | Phase 3 | Small molecule | TRPV1 |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.